• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

VIVA 17 Round-up: Medtronic touts real-world data for In.Pact Admiral drug-coated balloon

September 12, 2017 By Sarah Faulkner

Philips tests Stellerax low-dose DCB in PAD patients for two years

Royal PhilipsRoyal Philips (NYSE:PHG) today touted two-year data from the Illumenate trial evaluating the efficacy of its Stellarex 0.35” drug-coated balloon in patients with peripheral arterial disease.

The trial compared the company’s DCB with uncoated balloon angioplasty. The device, which Philips acquired when it bought Spectranetics in August, delivers a dose of just 2 micrograms of paclitaxel per square millimeter – a lower dose compared to other DCBs on the market.

The Illumenate trial included 328 patients with peripheral arterial disease, Philips said, and at 24 months, 75.9% of patients treated with Stellarex maintained blood flow through the treated section of the diseased artery. In comparison, just 61% of patients treated with an uncoated balloon maintained blood flow after 24 months.

“The Stellarex DCB produced durable results in this rigorous trial, validating earlier findings among the Illumenate trial series,” Dr. Marianne Brodmann said in prepared remarks. “These consistent, top-tier outcomes are achieved with a low-dose balloon. Stellarex is the first low-dose DCB to demonstrate a significant treatment effect at two years.”

“We are committed to providing proven clinical solutions that positively impact patient outcomes,” Christopher Barys, Philips’ Image Guided Therapy Devices business leader, added. “We are proud to have the only low-dose drug-coated balloon with a proven treatment effect at two years compared to the current endovascular standard of care in the U.S. The addition of Stellarex in the Philips portfolio through the Spectranetics acquisition reinforces our commitment to helping physicians decide, guide, treat and confirm the right therapy for their patients.”

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: acotecscientific, C.R. Bard, cook medical, Medtronic, Mercator MedSystems, Royal Philips, SurModics Inc.

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS